Berger Montague announced a securities fraud class action against Beta Bionics (BBNX) on behalf of investors who bought shares between July 30, 2025 and February 24, 2026. The lawsuit alleges the company misled investors about FDA observations at its manufacturing facility, claiming they only involved customer complaint handling when they actually concerned quality management, device malfunction investigation, and risk analysis. The complaint also says Beta Bionics failed to report serious injuries. The lead plaintiff deadline is November 3, 2026.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
